Biotech Industry Examiner

Menu
Menu
subscribe now
Search
Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?

Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?

With a $130m Series B, the startup is betting that

Unlocking New Frontiers: How Generative AI is Transforming Protein Design and Drug Discovery

Unlocking New Frontiers: How Generative AI is Transforming Protein Design and Drug Discovery

Abstract This report explores the transformative impact of generative artificial

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T

Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case

Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

The FDA wants to “pre-check” factories before the medicine exists

The FDA wants to “pre-check” factories before the medicine exists

MOST POPULAR

News

The FDA wants to “pre-check” factories before the medicine exists
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier
Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top